Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

被引:0
|
作者
Ahmad, Zahoor [1 ]
Tyagi, Sandeep [1 ]
Minkowski, Austin [1 ]
Almeida, Deepak [1 ]
Nuermberger, Eric L. [1 ]
Peck, Kaitlin M. [2 ]
Welch, John T. [2 ]
Baughn, Anthony S. [3 ]
Jacobs, Williams R., Jr. [3 ]
Grosset, Jacques H. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA
[2] SUNY Albany, Dept Chem, Albany, NY 12222 USA
[3] Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10467 USA
基金
美国国家卫生研究院;
关键词
Experimental chemotherapy; mouse; pyrazinamide; tuberculosis; VITRO ANTIMYCOBACTERIAL ACTIVITY; PYRAZINOIC ACID-ESTERS; ANTITUBERCULOSIS ACTIVITY; DRUG PYRAZINAMIDE; TUBERCLE BACILLI; MURINE MODEL; MUTATIONS; PNCA;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens. This drug has a unique sterilizing activity against Mycobacterium tuberculosis. Its unique role in tuberculosis treatment has lead to the search and development of its structural analogues. One such analogue is 5-chloro-pyrazinamide (5-Cl-PZA) that has been tested under in vitro conditions against M.-tuberculosis. The present study was designed with an aim to assess the activity of 5-Cl-PZA, alone and in combination with first-line drugs, against murine tuberculosis. Methods: The minimum inhibitory concentration (MIC) of 5-Cl-PZA in Middlebrook 7119 broth (neutral pH) and the inhibitory titre of serum from mice that received a 300 mg/kg oral dose of 5-Cl-PZA 30 min before cardiac puncture were determined. To test the tolerability of orally administered 5-Cl-PZA, uninfected mice received doses up to 300 mg/kg for 2 wk. Four weeks after low-dose aerosol infection either with M. tuberculosis or M. bovis, mice were treated 5 days/wk with 5-Cl-PZA, at doses ranging from 37.5 to 150 mg/kg, either alone or in combination with isoniazid and rifampicin. Antimicrobial activity was assessed by colony-forming unit counts in lungs after 4 and 8 wk of treatment. Results: The MIC of 5-Cl-PZA against M. tuberculosis was between 12.5 and 25 mu g/ml and the serum inhibitory titre was 1:4. Under the same experimental conditions, the MIC of pyrazinamide was >100 mu g/ml and mouse serum had no inhibitory activity after a 300 mg/kg dose; 5-Cl-PZA was well tolerated in uninfected and infected mice up to 300 and 150 mg/kg, respectively. While PZA alone and in combination exhibited its usual antimicrobial activity in mice infected with M. tuberculosis and no activity in mice infected with M. bovis, 5-Cl-PZA exhibited antimicrobial activity neither in mice infected with M tuberculosis nor in mice infected with IV. bovis. Interpretation & conclusion: Our findings showed that 5-Cl-PZA at doses up to 150 mg/kg was not active in chronic murine TB model. Further studies need to be done to understand the mechanism and mode of inactivation in murine model of tuberculosis.
引用
下载
收藏
页码:808 / 814
页数:7
相关论文
共 50 条
  • [1] The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis
    Martins, Marta
    Viveiros, Miguel
    Kristiansen, Jette E.
    Molnar, Joseph
    Amaral, Leonard
    IN VIVO, 2007, 21 (05): : 771 - 775
  • [2] DIFFERENTIATION OF MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM BOVIS
    FODOR, T
    VANDRA, E
    ACTA MICROBIOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1968, 15 (04): : 307 - &
  • [3] Tuberculosis patients co-infected with Mycobacterium bovis and Mycobacterium tuberculosis in an urban area of Brazil
    Silva, Marcio Roberto
    Rocha, Adalgiza da Silva
    da Costa, Ronaldo Rodrigues
    de Alencar, Andrea Padilha
    de Oliveira, Vania Maria
    Fonseca Junior, Antonio Augusto
    Sales, Mariana Lazaro
    Issa, Marina de Azevedo
    Soares Filho, Paulo Martins
    Vianello Pereira, Omara Tereza
    dos Santos, Eduardo Calazans
    Mendes, Rejane Silva
    de Jesus Ferreira, Angela Maria
    Pinto Coelho Mota, Pedro Moacyr
    Suffys, Philip Noel
    Crosland Guimaraes, Mark Drew
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2013, 108 (03): : 321 - 327
  • [4] The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
    Sun, Qingan
    Li, Xiaojun
    Perez, Lisa M.
    Shi, Wanliang
    Zhang, Ying
    Sacchettini, James C.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [5] Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection
    Manca, Claudia
    Koo, Mi-Sun
    Peixoto, Blas
    Fallows, Dorothy
    Kaplan, Gilla
    Subbian, Selvakumar
    PLOS ONE, 2013, 8 (08):
  • [6] The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
    Qingan Sun
    Xiaojun Li
    Lisa M. Perez
    Wanliang Shi
    Ying Zhang
    James C. Sacchettini
    Nature Communications, 11
  • [7] Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis
    Sheen, Patricia
    Ferrer, Patricia
    Gilman, Robert H.
    Lopez-Llano, Jon
    Fuentes, Patricia
    Valencia, Eddy
    Zimic, Mirko J.
    TUBERCULOSIS, 2009, 89 (02) : 109 - 113
  • [8] MIXED INFECTION WITH MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM BOVIS
    HEJNY, J
    SCANDINAVIAN JOURNAL OF RESPIRATORY DISEASES, 1968, 49 (01): : 62 - +
  • [9] Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M-bovis-infected cattle
    Mustafa, A. S.
    Skeiky, Y. A.
    Al-Attiyah, R.
    Alderson, M. R.
    Hewinson, R. G.
    Vordermeier, H. M.
    INFECTION AND IMMUNITY, 2006, 74 (08) : 4566 - 4572
  • [10] Domestic pigs experimentally infected with Mycobacterium bovis and Mycobacterium tuberculosis exhibit different disease outcomes
    Niroula, Nirajan
    Lim, Ze Long
    Walker, Stewart
    Huang, Yanyun
    Gerdts, Volker
    Zriba, Slim
    Drever, Kylee
    Chen, Jeffrey M.
    TUBERCULOSIS, 2022, 133